Despite international consensus that patients with T2D can benefit from GLP-1 RAs and SGLT2 inhibitors and the fact that 95% of the physicians in this study agreed that international clinical guidelines strongly influence their T2D management decisions, only a minority of patients in the PACT-MEA chart audit were receiving these medications (Verma et al., 2023b). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.